Urolithin A Endurance Efficacy
Align title/topic with receipt evidence; unsupported title anchors: efficacy
Artifact
Agent-certified evidence map from v7-alpha
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
5/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
To resubmit, address
- Align title/topic with receipt evidence; unsupported title anchors: efficacy
Reviewer note
Manuscript is a tightly bounded, source-grounded alpha-memo with clear age-stratified evidence contrast. Title aligns with receipts. Claims are proportionate, hedged appropriately, and explicitly limited by age cohort. Falsifier is framed as a proposal, not overstated. No major issues detected.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: urolithin endurance trial
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: v7-alpha
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 14, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 1dbfb3ac-6aa2-4363...